Screener
Summit Therapeutics SMMT Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
FAQ
- What is Summit Therapeutics's free cash flow?
- Summit Therapeutics (SMMT) reported free cash flow of -$122.54M in Q1 2026.
- How has Summit Therapeutics's free cash flow changed year-over-year?
- Summit Therapeutics's free cash flow decreased by 99.0% year-over-year, from -$61.59M to -$122.54M.
- What is the long-term trend for Summit Therapeutics's free cash flow?
- Over 3 years (2021 to 2025), Summit Therapeutics's free cash flow has grown at a 64.3% compound annual growth rate (CAGR), from -$72.89M to -$323.59M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Summit Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude